Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IMV Inc. (T:IMV)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IMV within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 20, 2020 07:05 ET
IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will host a conference call & webcast to report topline results from DeCidE1, an ongoing Phase 2 study evaluating its lead compound, DPX-Survivac, in patients with advanced recurrent ovarian cancer, on Tuesday, February 25, 2020 at 8:00 am EST.
Read full article
Feb 14, 2020 07:05 ET
IMV Announces Board Retirement
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of Directors effective February 28th, 2020.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.46
--
--
Price to Sales - TTM
563.35
16.82
10.24
Price to Book - most recent quarter
21.78
3.38
2.09
Price to Cash Flow per share - TTM
--
31.32
12.33
Price to Free Cash Flow per share - TTM
--
1.27
18.32
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 31, 202088,548-26,472
Jan 15, 2020115,0206,261
Dec 31, 2019108,759-11,494
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

IMV Inc. is a clinical-stage biopharmaceutical company focused on immunotherapy in oncology. The Company's drug delivery platform (DPX) enables the programming of immune cells in vivo. The Company's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is a monotherapy in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications.

See business summary

Twitter

Search (past week) for $IMV.CA

  • No tweets found